Home » Stocks » APTO

Aptose Biosciences, Inc. (APTO)

Stock Price: $5.12 USD -0.36 (-6.57%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $5.21 +0.09 (1.76%) Apr 16, 5:57 PM
Market Cap 454.12M
Revenue (ttm) n/a
Net Income (ttm) -55.24M
Shares Out 88.86M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $5.12
Previous Close $5.48
Change ($) -0.36
Change (%) -6.57%
Day's Open 5.44
Day's Range 5.07 - 5.50
Day's Volume 1,299,189
52-Week Range 3.39 - 9.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underly...

1 week ago - GlobeNewsWire

Aptose Biosciences Inc. (NASDAQ: APTO) shares traded higher after the company's release of fourth-quarter results Tuesday.  The stock gained 66.21% in Wednesday's regular session, closing at $6.10.

3 weeks ago - Benzinga

The company reported very encouraging results from an early-stage study.

3 weeks ago - The Motley Fool

APTO stock is rocketing this morning as the company releases some encouraging research details alongside its Q4 earnings report. The post APTO Stock: Why Aptose Biosciences Is Rocketing Higher Today app...

3 weeks ago - InvestorPlace

- Conference call and webcast at 5pm EDT today -

3 weeks ago - GlobeNewsWire

George Melko, Pharm.D. joins as Vice President, Regulatory Affairs

1 month ago - GlobeNewsWire

SAN DIEGO and TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underly...

1 month ago - GlobeNewsWire

Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.

3 months ago - Zacks Investment Research

Aptose shares are weak in post-ASH trading as the Phase I CG-806 study has yet to produce a clinical response in B-cell malignancies. Three B-cell patients did see some tumor reduction at lower doses of...

4 months ago - Seeking Alpha

SAN DIEGO and TORONTO, Dec. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today released highlights from a corporate update event held on Sunday, December 6th,...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

Corporate event to provide clinical update for CG-806 in AML and B-cell Cancers

4 months ago - GlobeNewsWire

Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.

Other stocks mentioned: FPRX
5 months ago - The Motley Fool

Aptose shares have been weak of late, but there have been no negative updates to the company's core clinical programs, and management recently started its third trial (CG-806 in AML). It is unclear whet...

5 months ago - Seeking Alpha

Aptose Biosciences' (APTO) CEO William Rice on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level

5 months ago - GlobeNewsWire

Abstracts Accepted for Presentation Abstracts Accepted for Presentation

5 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlyi...

5 months ago - GlobeNewsWire

Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.

5 months ago - Zacks Investment Research

Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg Phase 1 a/b Study of CG-806 in AML Initiates with Starting Dose of 450mg

5 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under...

7 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the under...

7 months ago - GlobeNewsWire

Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

APTO's lead candidate, CG-806, is due for important updates in 4Q2020.

7 months ago - Seeking Alpha

SAN DIEGO and TORONTO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlyi...

8 months ago - GlobeNewsWire

Aptose has recently raised more cash, and looks set for its foreseeable clinical trial needs.

8 months ago - Seeking Alpha

Aptose Biosciences Inc. (APTO) CEO William Rice on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SAN DIEGO and TORONTO, July 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underl...

8 months ago - GlobeNewsWire

Dilution is on the way.

9 months ago - The Motley Fool

SAN DIEGO and TORONTO, July 15, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS) today announced that it has commenced an underwritten public offer...

9 months ago - GlobeNewsWire

Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML

9 months ago - GlobeNewsWire

Can the run for Sarepta Therapeutics, Viela Bio, and Aptose Biosciences continue?

Other stocks mentioned: SRPT, VIE
9 months ago - The Motley Fool

Safety, tolerability and phospho-BTK inhibition at first three CG-806 dose levels in patients with CLL and other B-cell malignancies

10 months ago - GlobeNewsWire

SAN DIEGO and TORONTO, June 02, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therape...

10 months ago - GlobeNewsWire

Aptose Biosciences' (APTO) CEO William Rice on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SAN DIEGO and TORONTO, May 05, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents t...

11 months ago - GlobeNewsWire

Data from patients at first two dose levels; Phase 1a/b study is ongoing Data from patients at first two dose levels; Phase 1a/b study is ongoing

11 months ago - GlobeNewsWire

Aptose Riding Higher As The Street Starts Paying Attention

1 year ago - Seeking Alpha

Aptose Biosciences Inc. (APTO) CEO William Rice on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

Investing in this emerging cancer-focused biotech may just allow you to retire early.

1 year ago - The Motley Fool

Top Ranked Momentum Stocks to Buy for January 29th

Other stocks mentioned: AGYS, ENPH, VERU
1 year ago - Zacks Investment Research

Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

SAN DIEGO and TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwrit...

1 year ago - GlobeNewsWire

Investors excited about the biotech's prospects are taking the opportunity to buy on the dip following the announcement of a new stock offering.

1 year ago - The Motley Fool

Promising preclinical data and the acquisition of another small biotech continued to generate enthusiasm among investors.

1 year ago - The Motley Fool

SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting t...

1 year ago - GlobeNewsWire

Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253 Aptose Management and KOL’s Discuss Early Clinical Observations with CG-806 and APTO-253

1 year ago - GlobeNewsWire

SAN DIEGO and TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlyi...

1 year ago - GlobeNewsWire

About APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the t... [Read more...]

Industry
Biotechnology
Founded
1986
CEO
William Rice
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
APTO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for APTO stock is "Buy." The 12-month stock price forecast is 4.72, which is a decrease of -7.81% from the latest price.

Price Target
$4.72
(-7.81% downside)
Analyst Consensus: Buy